5 Scopus citations


The discovery of antidepressant medications more than 50 years ago was one of the major breakthroughs in medical science. Today, the field of antidepressant drug development is experiencing a paradigm shift. Changing perceptions regarding the neurobiology of depression and the serendipitous discovery of ketamine’s rapid antidepressant effects have ushered in a new era of innovative research and novel drug development. This chapter provides a selective review of the suspected mechanisms of ketamine’s rapid antidepressant action in human subjects gleaned from multiple controlled and open-label trials. We also briefly review the underlying neurobiology of depression, potential biomarkers of ketamine response, the efficacy and safety profile of ketamine, current limitations to its widespread use, and considerations for novel drug development that hold promise for improved psychotherapeutic treatments for depressive and trauma-related disorders.

Original languageEnglish
Title of host publicationKetamine for Treatment-Resistant Depression
Subtitle of host publicationThe First Decade of Progress
PublisherSpringer International Publishing
Number of pages23
ISBN (Electronic)9783319429250
ISBN (Print)9783319429236
StatePublished - 1 Jan 2016


Dive into the research topics of 'Ketamine’s mechanism of rapid antidepressant activity: Evidence gleaned from clinical studies'. Together they form a unique fingerprint.

Cite this